Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
365
NCT05430412
CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis
Phase: N/A
Role: Lead Sponsor
Start: Jan 11, 2022
Completion: Oct 31, 2024
NCT05636709
National GMA Post-market Clinical Follow-up Study (GRACE)
Completion: Jun 30, 2026